NPPB and pulmonary arterial hypertension: Serum biomarkers are objective, noninvasive and easily obtained, but to date, only the brain natriuretic peptide and its N-terminal pro-brain natriuretic peptide (NTproBNP) are commonly used in clinical practice for PAH risk stratification.